0001127602-23-001340.txt : 20230112 0001127602-23-001340.hdr.sgml : 20230112 20230112161121 ACCESSION NUMBER: 0001127602-23-001340 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230110 FILED AS OF DATE: 20230112 DATE AS OF CHANGE: 20230112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Colangelo Dominick CENTRAL INDEX KEY: 0001313403 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 23526041 MAIL ADDRESS: STREET 1: 1000 WINTER ST. STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-01-10 0000887359 Vericel Corp VCEL 0001313403 Colangelo Dominick C/O VERICEL CORPORATION CAMBRIDGE MA 02139 1 1 President and CEO Common Stock 2023-01-10 4 M 0 39938 25.80 A 197004 D Common Stock 2023-01-10 4 S 0 39938 27.132 D 157066 D Stock Option (Right to Buy) 25.80 2023-01-10 4 M 0 39938 0 D 2023-03-06 Common Stock 39938 0 D These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. /s/ Sean Flynn, as Attorney-in-Fact for Dominick C. Colangelo 2023-01-12